Last edition
News about "zasocitinib plaque psoriasis treatment"
Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study
Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.
Zasocitinib Plaque Psoriasis Treatment | 30/03/2026 | By News Bureau | 173
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members